Convalescent Plasma Therapy Market Report 2026

The convalescent plasma therapy market size has grown rapidly in recent years. It will grow from $0.06 billion in 2025 to $0.06 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to urgent pandemic treatment demand, lack of targeted therapeutics, availability of recovered donors, emergency use authorizations, hospital-based plasma transfusion.

The convalescent plasma therapy market size is expected to see rapid growth in the next few years. It will grow to $0.11 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to preparedness for future outbreaks, advancements in antibody testing, improved plasma storage technologies, expansion of transfusion services, research into immune therapies. Major trends in the forecast period include increased use in emerging infectious disease treatment, growing focus on high-titer antibody plasma, expansion of plasma collection infrastructure, improved donor screening and selection, integration with hospital-based critical care.

The increasing prevalence of infectious diseases is expected to support the growth of the convalescent plasma therapy market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread between individuals or through contaminated environments. The prevalence of these diseases is rising due to factors such as growing urbanization and increased global travel, which contribute to closer human interaction and faster transmission of pathogens. Convalescent plasma therapy supports the treatment of infectious diseases by using plasma collected from recovered patients that contains antibodies capable of neutralizing pathogens and providing passive immunity to infected individuals, thereby strengthening the body’s immune response. For example, in October 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, around 8.2 million people were newly diagnosed with tuberculosis in 2023, up from 7.5 million cases in 2022, marking the highest number recorded since global tuberculosis surveillance began. Therefore, the rising prevalence of infectious diseases is contributing to the growth of the convalescent plasma therapy market.

The growth in the number of hospitals is also expected to drive the expansion of the convalescent plasma therapy market going forward. A hospital is a specialized healthcare facility that provides comprehensive medical services, including diagnosis, treatment, and patient care for a wide range of illnesses and conditions. An increase in hospital numbers is often associated with improvements in healthcare infrastructure, which leads to better capabilities for collecting, processing, and administering convalescent plasma and enhances the overall quality of care. For instance, in April 2025, according to the Hellenic Statistical Authority, a Greece-based national government statistics agency, the number of hospitals in Greece rose from 265 units in 2022 to 266 units in 2023, reflecting a 0.4% increase. As a result, the growing number of hospitals is supporting the growth of the convalescent plasma therapy market.

Companies operating in the convalescent plasma therapy market are increasingly focusing on the development of innovative approaches such as hyperimmune globulin therapies to improve treatment effectiveness and address limitations associated with conventional plasma therapies. Hyperimmune globulin therapies involve the use of plasma with a high concentration of specific antibodies obtained from individuals who have recovered from an infection, providing targeted and potent immune support to patients. For example, in October 2023, Kamada Ltd., an Israel-based biopharmaceutical company, announced notable progress related to its product CYTOGAM (Cytomegalovirus Immune Globulin Intravenous [Human]), which became commercially available in the United States following FDA approval of its manufacturing facility in Israel. During IDWeek 2023, newly presented clinical data demonstrated a five-year survival benefit for high-risk cytomegalovirus mismatch lung transplant patients treated with CYTOGAM. In addition, Kamada established its first Scientific Advisory Board to further strengthen U.S. clinical programs for the product.

Major companies operating in the convalescent plasma therapy market are Bio Farma, Biotest AG, BPL Ltd., LFB SA, Octapharma AG, CSL Behring LLC, Takeda Pharmaceutical Company Ltd., Orthosera Kft., ADMA Biologics Inc., GC Biopharma Corp, Grifols S.A, Sanquin Plasma Products B.V., America's Blood Centers, Blood Centers of America Inc., New York Blood Center, Blood Systems Inc., OneBlood Inc., Gulf Coast Regional Blood Center, Bloodworks Northwest, Blood Assurance Inc., Honolulu Blood-Plasma Bank, Community Blood Center, LifeStream Blood Bank, Kedrion Biopharma Inc.

North America was the largest region in the convalescent plasma therapy market in 2025. Western Europe was the second largest region in the convalescent plasma therapy market. The regions covered in the convalescent plasma therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the convalescent plasma therapy market by increasing costs of imported plasma collection equipment, storage systems, diagnostic assays, and laboratory consumables. Hospitals and blood banks in North America and Europe are most affected due to reliance on imported medical equipment, while Asia-Pacific faces higher infrastructure costs. These tariffs are increasing therapy-related expenses. However, they are also encouraging domestic equipment manufacturing, regional plasma infrastructure development, and stronger healthcare preparedness systems.

The convalescent plasma therapy market research report is one of a series of new reports that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Convalescent plasma therapy involves the use of plasma collected from individuals who have recovered or are in the recovery phase of an illness and contains antibodies against the pathogen responsible for the infection. This plasma is used to treat patients who are infected with the corresponding microorganism.

The primary antibody types involved in convalescent plasma therapy include IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that plays a key role in immune activity at mucous membranes. The therapy is applied for purposes such as prophylaxis and treatment and is utilized across various settings, including hospitals and clinics, laboratories, and research institutes.

The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.